Quantcast
Environmental News for a Healthier Planet and Life

Help Support EcoWatch

Coca-Cola

Coca-Cola intentionally funded the Global Energy Balance Network (GEBN) as a "weapon" in a "growing war between the public health community and private industry" on the causes of obesity, according to a press release sent to EcoWatch by consumer group U.S. Right to Know.

The quotes come from documents obtained in a Freedom of Information Request filed by U.S. Right to Know that formed the basis for a study published Wednesday in the Journal of Epidemiology and Community Health. The study's authors focused on the documents because they definitively proved that Coca-Cola funded the GEBN with the intention of influencing public health debate in their favor.

Read More Show Less

EcoWatch Daily Newsletter

By Carey Gillam

Four months after the publication of a batch of internal Monsanto Co. documents stirred international controversy, a new trove of company records was released early Tuesday, providing fresh fuel for a heated global debate over whether or not the agricultural chemical giant suppressed information about the potential dangers of its Roundup herbicide and relied on U.S. regulators for help.

Read More Show Less

Monsanto, the maker of the glyphosate-based herbicide Roundup, filed a motion June 16 in U.S. District Court, Northern District of California to reconsider the chemical's addition to California's Proposition 65 list of agents known to cause cancer.

The agrochemical giant made this move based on a June 14 Reuters investigation of Dr. Aaron Blair, a lead researcher on the World Health Organization's International Agency for Research on Cancer (IARC) committee, that classified glyphosate as a "2A probable human carcinogen" in March 2015.

Read More Show Less

Support Ecowatch

www.youtube.com

By Stacy Malkan

Some industry messaging efforts are so heavy-handed they end up highlighting their own PR tactics more than the message they are trying to convey. That's the problem with Food Evolution, a new documentary by Academy Award-nominated director Scott Hamilton Kennedy and narrated by Neil deGrasse Tyson.

Read More Show Less

Trending

By Carey Gillam

In a well-orchestrated and highly coordinated media coup, Monsanto Co. and friends this week dropped a bombshell on opponents who are seeking to prove that the company's beloved Roundup herbicide causes cancer.

A widely circulated story published June 14 in the global news outlet Reuters (for which I formerly worked) laid out what appeared to be a scandalous story of hidden information and a secretive scientist, "exclusive" revelations that the story said could have altered a critical 2015 classification that associated Monsanto's Roundup to cancer and triggered waves of lawsuits against Monsanto.

Read More Show Less

By Carey Gillam

The U.S. Department of Agriculture (USDA) has quietly dropped a plan to start testing food for residues of glyphosate, the world's most widely used weed killer and key ingredient in Monsanto's branded Roundup herbicides.

Read More Show Less

By Carey Gillam

Nearly a year after a mysterious leak of industry-friendly information from the U.S. Environmental Protection Agency (EPA), many pressing questions remain about the agency's interactions with agribusiness giant Monsanto and its handling of cancer concerns with Monsanto's top-selling herbicide. But thanks to a federal court judge in California, we may soon start getting some answers.

Read More Show Less
Photo credit: Wikimedia Commons

U.S. Right to Know, a consumer advocacy organization, filed a federal lawsuit Thursday against the U.S. Environmental Protection Agency (EPA) for violating provisions of the Freedom of Information Act (FOIA). Public Citizen Litigation Group, a public interest law firm in Washington, DC, is representing U.S. Right to Know in the action.

Read More Show Less

Trending

Former U.S. Environmental Protection Agency (EPA) official Jess Rowland may have to testify over claims that he covered up evidence that glyphosate, the main ingredient in Monsanto's top-selling herbicide Roundup, could cause cancer.

A federal judge said at a hearing in San Francisco on Monday that he is likely to grant the deposition of Rowland, a key figure named in multi-district cancer lawsuits alleging that Monsanto failed to warn about the cancer risks associated with exposure to glyphosate.

"My reaction is when you consider the relevance of the EPA's reports, and you consider their relevance to this litigation, it seems appropriate to take Jess Rowland's deposition," U.S. District Judge Vince Chhabria said at the hearing.

The plaintiffs' lawyers argue that Rowland had a "highly suspicious" relationship with Monsanto, Bloomberg reported.

Rowland, a former deputy division director at the EPA, chaired the agency's Cancer Assessment Review Committee (CARC). The CARC determined that glyphosate was "not likely to be carcinogenic to humans," which differs from the International Agency for Research on Cancer conclusion that glyphosate was a probable human carcinogen. Rowland left the agency just days after a copy of the CARC report was leaked to the press in May 2016.

This new development in the case—Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco)—is yet another litigious nightmare for the St. Louis-based agrochemical giant, which is pending acquisition from Bayer AG. Incidentally, the German pharmaceutical company recently signaled that its $66 billion mega-merger with Monsanto may face delays amid regulatory concerns.

In response, Monsanto insisted that glyphosate is safe and does not cause cancer.

"While we empathize with anyone facing these terrible illnesses, there is no evidence that glyphosate is the cause," Scott Partridge, Monsanto's Vice President of Global Strategy, said in a statement published by Bloomberg. "The very long and well-established history of safe glyphosate use—over 40 years in more than 160 countries—shows clearly that these claims are supported neither by the science nor the facts."

As U.S. Right to Know reported, the litigation involves more than 60 plaintiffs accusing Monsanto of covering up evidence that Roundup herbicide could cause cancer. The plaintiffs, all of whom are suffering from non-Hodgkin's lymphoma or lost a loved one to the disease, have asserted in recent court filings that Monsanto wielded significant influence within the EPA's Office of Pesticide Programs (OPP), and had close ties specifically to Rowland, who until last year was deputy division director within the health effects division of the OPP.

A Feb. 10 court filing includes correspondence dated March 4, 2013, from a 30-year career EPA scientist Marion Copley accusing Rowland of playing "political conniving games with the science" to favor pesticide companies such as Monsanto.

Citing evidence from animal studies, Copley wrote, "It is essentially certain that glyphosate causes cancer." Copley went on to say that Rowland and another official "intimidated staff" into changing reports related to the glyphosate findings.

According to Bloomberg, Raven M. Norris, a lawyer at the U.S. Attorney's Office in San Francisco representing the EPA, said it was "premature" to take Rowland's testimony.

The EPA has until March 28 to file written arguments opposing Rowland's deposition.

By Carey Gillam

A new court filing made on behalf of dozens of people claiming Monsanto's Roundup herbicide gave them cancer includes information about alleged efforts within the U.S. Environmental Protection Agency (EPA) to protect Monsanto's interests and unfairly aid the agrichemical industry.

The filing, made late Friday by plaintiff's attorneys, includes what the attorneys represent to be correspondence from a 30-year career EPA scientist accusing top-ranking EPA official Jess Rowland of playing "your political conniving games with the science" to favor pesticide manufacturers such as Monsanto. Rowland oversaw the EPA's cancer assessment for glyphosate, the key ingredient in Monsanto's weed-killing products, and was a key author of a report finding glyphosate was not likely to be carcinogenic. But in the correspondence, longtime EPA toxicologist Marion Copley cites evidence from animal studies and writes: "It is essentially certain that glyphosate causes cancer."

Attorneys for the plaintiffs declined to say how they obtained the correspondence, which is dated March 4, 2013. The date of the letter comes after Copley left the EPA in 2012 and shortly before she died from breast cancer at the age of 66 in January 2014. She accuses Rowland of having "intimidated staff" to change reports to favor industry, and writes that research on glyphosate, the key ingredient in Monsanto's Roundup, shows the pesticide should be categorized as a "probable human carcinogen." The International Agency for Research on Cancer, an arm of the World Health Organization, declared as much—that glyphosate was a probable human carcinogen—in March 2015 after reviewing multiple scientific studies. Monsanto has rejected that classification and has mounted a campaign to discredit IARC scientists.

The communication, if authentic, could be an explosive development in the snowballing multi-district litigation that now includes more than 60 plaintiffs from around the United States accusing Monsanto of covering up evidence that Roundup herbicide could cause cancer. The plaintiffs, all of whom are suffering from non-Hodgkin's lymphoma (NHL) or lost a loved one to NHL, have asserted in recent court filings that Monsanto wielded significant influence within the EPA's Office of Pesticide Programs (OPP), and had close ties specifically to Rowland, who until last year was deputy division director within the health effects division of the OPP. Rowland managed the work of scientists who assessed human health effects of exposures to pesticides like glyphosate and he chaired the EPA's Cancer Assessment Review Committee (CARC) that determined glyphosate was "not likely to be carcinogenic to humans." Rowland left the EPA in 2016, shortly after a copy of the CARC report was leaked and cited by Monsanto as evidence that the IARC classification was flawed.

Lawyers for the plaintiffs want the federal judge in the case to lift a seal on documents that detail Monsanto's interactions with Rowland regarding the EPA's safety assessment of glyphosate. Monsanto turned the documents over in discovery but marked them "confidential," a designation plaintiffs' attorneys say is improper. They also want to depose Rowland. But Monsanto and the EPA object to the requests, court documents show. Rowland could not be reached for comment, and the EPA declined to comment about the court matters.

Trending

Mike Mozart

By Carey Gillam

Monsanto and officials within the U.S. Environmental Protection Agency (EPA) are fighting legal efforts aimed at exploring Monsanto's level of influence over regulatory assessments of the key chemical in the company's Roundup herbicide, new federal court filings show.

The revelations are contained in a series of filings made within the last few days in the U.S. District Court for the Northern District of California as part of litigation brought by more than 50 people who are suing Monsanto. The plaintiffs claim they or their loved ones developed non-Hodgkin lymphoma after exposure to Roundup herbicide, and that Monsanto has spent decades covering up the chemical's cancer risks.

Lawyers for the plaintiffs want the court to lift a seal on documents that detail Monsanto's interactions and discussions with former top EPA brass Jess Rowland regarding the EPA's safety assessment of glyphosate, the active ingredient in Roundup. Monsanto turned the documents over in discovery but marked the documents "confidential," a designation plaintiffs' attorneys say is improper. They also want to depose Rowland. But Monsanto and the EPA are fighting both requests, the filings show.

The EPA has spent the last few years assessing the health and environmental safety aspects of glyphosate as global controversy over the chemical has mounted. The World Health Organization's International Agency for Research on Cancer (IARC) declared in March 2015 that glyphosate is a probable human carcinogen, with a positive association found between glyphosate and non-Hodgkin lymphoma. Monsanto has been fighting to refute that classification because of financial and legal liability ramifications.

Rowland has been key in Monsanto's efforts to rebut the IARC finding because until last year he was a deputy division director within the health effects division of the EPA's Office of Pesticide Programs, managing the work of scientists who assessed human health effects of exposures to pesticides like glyphosate. And, importantly, he chaired the EPA's Cancer Assessment Review committee (CARC) that issued an internal report in October 2015 contracting IARC's findings. That 87-page report, signed by Rowland, determined that glyphosate was "not likely to be carcinogenic."

The report was a godsend to Monsanto because it has helped bolster the company's defense against the Roundup liability lawsuits, and helped shore up market support for a product that brings in billions of dollars in revenues to the company annually. The EPA's stamp of approval for the safety of glyphosate has also been key to the success of Monsanto's genetically engineered, glyphosate-tolerant crops, which have been popular with farmers.

But the handling of the CARC report raised questions last year when it was "inadvertently" posted to a public EPA website on April 29, 2016, and kept on the site three days, before being pulled down. The agency said the report was not final and that it should not have been posted, but Monsanto touted the report as a public affirmation of its safety claims for glyphosate. The company also cited the report at a May court hearing in the Roundup litigation as a counter point to the IARC cancer classification. Shortly after the CARC report was removed from the EPA website, Rowland left his 26-year career at the EPA.

Plaintiffs' attorneys have asked to depose Rowland to learn about that situation and other dealings with Monsanto. But, along with Monsanto's objection to a release of the documents that relate to its conversations with Rowland, the EPA has specifically refused the deposition request, saying it would "not clearly be in the interests of EPA" to allow attorneys to question Rowland about the cancer review and interactions with Monsanto.

Monsanto has so far turned over roughly six million pages of documents through the court-ordered discovery process, but has designated roughly 85 percent of the information as "confidential," meaning plaintiffs' attorneys must black out information from those documents in any court filings that could be accessed by reporters or other members of the public. That designation is improper for many of the documents, especially ones dealing with the company's interactions with, and influence attempts over, EPA officials, plaintiffs' lawyers argue.

The lawyers said that the documents obtained through discovery show that "Monsanto has been confident all along that EPA would continue to support glyphosate, whatever happened and no matter who held otherwise." According to the court filings by plaintiffs' attorneys, the documents show "it is clear that Monsanto enjoyed considerable influence within the EPA's OPP, and was close with Mr. Rowland ... The documentary evidence strongly suggests that Mr. Rowland's primary goal was to serve the interests of Monsanto."

The EPA is a taxpayer-funded, public agency and its dealings with Monsanto should be subject to public scrutiny, particularly given the widespread use of glyphosate herbicide products and the current ongoing international debate over the safety of the chemical, the lawyers claim.

"The health and safety of millions of U.S. citizens is at stake," states the Jan. 16 plaintiffs' filing. "Decisions affecting the public health should not be based on secret conversations between Monsanto and EPA officials. If Monsanto wants to advocate on behalf of glyphosate to EPA employees, they should have to do it publicly, so that concerned citizens have equal opportunity to advocate for their health and the health of their families. This issue is too important to allow Monsanto to improperly influence the EPA, and then hide such communication behind an improper 'confidential' designation."

Monsanto is adamant that its documents not be made public, saying releasing them would be "premature and improper." Allowing public dissemination "of a few select internal corporate documents taken out of context … would be prejudicial to Monsanto and could cause reputational harm," the company's attorneys wrote in their response.

The plaintiffs' attorneys say at least four specific documents they have obtained are clearly in the public interest and "illuminate that one of Monsanto's chief business strategies is its secret and untoward influence on EPA." The documents include both internal memos and email chains, according to descriptions of the documents.

"Since Monsanto's communications with the EPA remain secret, these known lobbying efforts are only the tip of the iceberg of Monsanto's collusion with the EPA. Monsanto's bad acts in violating U.S. regulations through secret communications with the EPA should not by rewarded by allowing them to keep these communications secret by merely stamping them 'confidential,'" the plaintiffs' attorney state in the filings. "These documents summarize communications with EPA which are not elsewhere memorialized; they are not trade secrets and the public has a compelling interest in disclosure."

Monsanto argues otherwise, saying the four documents at issue "contain sensitive, non-public commercial information, relate to a motion seeking to obtain discovery from a non-party, and bear only a tangential, at best, connection to the questions at issue in this litigation; hence, any public interest 'is minimal.'"

U.S. District Jude Vince Chhabria, who is overseeing the multi-district Roundup litigation, could rule on these matters any day.

By Carey Gillam

As Americans gather with their families for Thanksgiving this week, new government data offers a potentially unappetizing assessment of the U.S. food supply—Residues of many types of bug-killing pesticides, fungicides and weed killing chemicals have been found in roughly 85 percent of thousands of foods tested.

Read More Show Less

By Carey Gillam

The U.S. Environmental Protection Agency (EPA) was slated to hold four days of public meetings, Oct. 18-21, focused on essentially one question: Is glyphosate, the world's most widely used herbicide, safe?

However, the EPA Scientific Advisory Panel (SAP) meetings were "postponed," just four days before they were suppose to meet, after intense lobbying by the agrichemical industry, including Monsanto. The industry first fought to keep the meetings from being held at all, and argued that if they were held, several leading international experts should be excluded from participating, including "any person who has publicly expressed an opinion regarding the carcinogenicity of glyphosate."

As the meetings drew near, CropLife America, which represents the interests of Monsanto and other agribusinesses, specifically took issue with at least two scientists chosen for the panel, alleging the experts might be unfavorably biased against industry interests. On Oct. 12, the group sent a letter to the EPA calling for Dr. Kenneth Portier of the American Cancer Society to be more deeply scrutinized for any "pre-formed conclusions" about glyphosate. More notably, CropLife called for leading epidemiologist Dr. Peter Infante to be completely disqualified from panel participation.

"EPA should replace Dr. Infante with an epidemiologist without such patent bias," CropLife told the EPA. The chemical industry group said Infante was unlikely to give industry-sponsored research studies the credibility the industry believes they deserve. CropLife said Infante has testified in the past for plaintiffs in chemical exposure cases against Monsanto.

Croplife also argued that because Infante was the "only epidemiologist on the glyphosate SAP" he would have enhanced influence in the evaluation of epidemiological data about glyphosate and cancer. The CropLife letter was dated Oct. 12 and by Oct. 14, the EPA announced it was looking for additional epidemiology expertise to ensure "robust representation from that discipline." The EPA also said one panelist had voluntarily departed, though the agency refused to say who that panelist was.

Challenging Infante's role is a gutsy move. After all, Infante spent 24 years working for the Occupational Safety and Health Administration helping determine cancer risks to workers during the development of standards for toxic substances, including asbestos, arsenic and formaldehyde. His resume includes a stint at the National Institute for Occupational Safety and Health where he conducted epidemiological studies related to carcinogens, and he has served as an expert consultant in epidemiology for several world bodies, including the EPA and the World Trade Organization.

According to sources close to the situation, Infante remains a panelist as of this week, but there is no certainty when the meetings might be rescheduled, and what the panel membership might look like when they are rescheduled. The EPA has refused to discuss who remains on the panel, but some onlookers believe that the EPA was clearly bowing to agrichemical industry interests.

"This is outrageous. The industry wants to say that our own government scientists, the top ones in their fields, aren't good enough for these panels," said Michael Hansen, senior staff scientist at the Consumers Union. "If the EPA wants to add extra epidemiologists that is great but why didn't they do it before? They are doing this because of pressure from industry."

The industry clearly has much at stake, as does the public. Glyphosate is the key ingredient in Monsanto's branded Roundup herbicides as well as herbicides marketed by numerous agrichemical companies around the world. It is also the key to what has been 20 years of sales of genetically engineered glyphosate-tolerant crops developed by Monsanto. The future sales of both the chemical and the crops are being jeopardized by the mounting concerns that glyphosate can cause cancer and other illnesses or disease.

Scientists around the world have been raising red flags for years over worrisome research findings, and last year the International Agency of Research on Cancer, said glyphosate was a probable human carcinogen. More than three dozen lawsuits have been filed against Monsanto by people claiming Roundup gave them non-Hodgkin lymphoma, and both European and U.S. regulators are evaluating the chemical for continued use.

Since the International Agency of Research on Cancer classification, Monsanto has asked the EPA to back industry assurances that glyphosate is safe, and so far, the EPA has done exactly that, issuing a series of reports and memos that dovetail with Monsanto's position. Monsanto also has sought to bolster arguments for glyphosate's safety by pointing to supportive research papers published in late September in Critical Reviews in Toxicology. Monsanto hired the group that arranged for the panel, and most of the 16 scientists involved are former Monsanto employees or Monsanto consultants. At least one, Gary Williams, has also consulted for Monsanto on litigation matters involving glyphosate.

It seems more than a little hypocritical that those scientists are presented as credible by the industry, but scientists like Infante and Portier are said to be unfit to advise the EPA because of suspected bias. Like Infante, Portier has a long track record as an independent scientist. He is vice president of the Statistics & Evaluation Center at the American Cancer Society. He has participated in more than 60 other SAP meetings and has served on expert and advisory panels for the National Institutes of Health, National Institute of Environmental Health Sciences, the National Toxicology Program, and the World Health Organization Food and Agriculture Organization.

Portier also would not comment about the industry concerns about him, the postponement or changes to the makeup of the SAP, other than to say that as of today, he remains on the panel. EPA said it is "working to reschedule as soon as possible." But the delay and the maneuvering by industry to influence panel participation does little to bolster consumer confidence for the likelihood of an objective outcome.